Use of beta‐blockers, angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta‐analysis
Breast cancer (BC) is the second leading cause of cancer death among women in Western Countries. Beta‐blocker (BB) drugs, angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) were suggested to have a favorable role in the development and progression of BC. We have...
Saved in:
| Published in | International journal of cancer Vol. 139; no. 1; pp. 212 - 219 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.07.2016
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0020-7136 1097-0215 |
| DOI | 10.1002/ijc.30062 |
Cover
| Abstract | Breast cancer (BC) is the second leading cause of cancer death among women in Western Countries. Beta‐blocker (BB) drugs, angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) were suggested to have a favorable role in the development and progression of BC. We have performed a meta‐analysis to clarify the potential benefits of these drugs on BC survival. A total number of 46 265 BC patients from eleven papers were included, ten independent studies on BB use and seven on ACEi/ARB use. The summary hazard ratio (SHR) was estimated by pooling the study‐specific estimates with random effects models and maximum likelihood estimation. We assessed the homogeneity of the effects across studies and evaluated between‐study heterogeneity by meta‐regression and sensitivity analyses. We found a significant improvement in BC specific survival for patients treated with BB drugs at the time of BC diagnosis (SHR: 0.44; 95%CI: 0.26–0.73 with I2 = 78%). We also observed a borderline significant improvement in disease free survival for subjects treated with BB (SHR: 0.71, 95%CI: 0.19–1.03). No association of ACEi/ARB use with disease free and overall survival was found. In conclusion, we report epidemiological evidence that BB improve BC‐specific survival. Clinical trials addressing this hypothesis are warranted.
What's new?
Antihypertensive drugs are linked to reductions in tumor metastasis, tumor recurrence and cancer‐specific mortality, benefits possibly related to the drugs’ ability to blunt the effects of stress hormones and inflammation. Results from previous observational studies are controversial, however, particularly concerning breast cancer and whether taking antihypertensive drugs can actually improve survival. In the present meta‐analysis, which included some 46,265 patients from 11 articles, breast cancer‐specific survival was found to be significantly improved among patients who were undergoing treatment with beta‐blockers at the time of cancer diagnosis. The authors declare a need for further exploration in clinical trials. |
|---|---|
| AbstractList | Breast cancer (BC) is the second leading cause of cancer death among women in Western Countries. Beta-blocker (BB) drugs, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) were suggested to have a favorable role in the development and progression of BC. We have performed a meta-analysis to clarify the potential benefits of these drugs on BC survival. A total number of 46 265 BC patients from eleven papers were included, ten independent studies on BB use and seven on ACEi/ARB use. The summary hazard ratio (SHR) was estimated by pooling the study-specific estimates with random effects models and maximum likelihood estimation. We assessed the homogeneity of the effects across studies and evaluated between-study heterogeneity by meta-regression and sensitivity analyses. We found a significant improvement in BC specific survival for patients treated with BB drugs at the time of BC diagnosis (SHR: 0.44; 95%CI: 0.26-0.73 with I(2) = 78%). We also observed a borderline significant improvement in disease free survival for subjects treated with BB (SHR: 0.71, 95%CI: 0.19-1.03). No association of ACEi/ARB use with disease free and overall survival was found. In conclusion, we report epidemiological evidence that BB improve BC-specific survival. Clinical trials addressing this hypothesis are warranted. Breast cancer (BC) is the second leading cause of cancer death among women in Western Countries. Beta-blocker (BB) drugs, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) were suggested to have a favorable role in the development and progression of BC. We have performed a meta-analysis to clarify the potential benefits of these drugs on BC survival. A total number of 46 265 BC patients from eleven papers were included, ten independent studies on BB use and seven on ACEi/ARB use. The summary hazard ratio (SHR) was estimated by pooling the study-specific estimates with random effects models and maximum likelihood estimation. We assessed the homogeneity of the effects across studies and evaluated between-study heterogeneity by meta-regression and sensitivity analyses. We found a significant improvement in BC specific survival for patients treated with BB drugs at the time of BC diagnosis (SHR: 0.44; 95%CI: 0.26-0.73 with I2=78%). We also observed a borderline significant improvement in disease free survival for subjects treated with BB (SHR: 0.71, 95%CI: 0.19-1.03). No association of ACEi/ARB use with disease free and overall survival was found. In conclusion, we report epidemiological evidence that BB improve BC-specific survival. Clinical trials addressing this hypothesis are warranted. What's new? Antihypertensive drugs are linked to reductions in tumor metastasis, tumor recurrence and cancer-specific mortality, benefits possibly related to the drugs' ability to blunt the effects of stress hormones and inflammation. Results from previous observational studies are controversial, however, particularly concerning breast cancer and whether taking antihypertensive drugs can actually improve survival. In the present meta-analysis, which included some 46,265 patients from 11 articles, breast cancer-specific survival was found to be significantly improved among patients who were undergoing treatment with beta-blockers at the time of cancer diagnosis. The authors declare a need for further exploration in clinical trials. Breast cancer (BC) is the second leading cause of cancer death among women in Western Countries. Beta‐blocker (BB) drugs, angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) were suggested to have a favorable role in the development and progression of BC. We have performed a meta‐analysis to clarify the potential benefits of these drugs on BC survival. A total number of 46 265 BC patients from eleven papers were included, ten independent studies on BB use and seven on ACEi/ARB use. The summary hazard ratio (SHR) was estimated by pooling the study‐specific estimates with random effects models and maximum likelihood estimation. We assessed the homogeneity of the effects across studies and evaluated between‐study heterogeneity by meta‐regression and sensitivity analyses. We found a significant improvement in BC specific survival for patients treated with BB drugs at the time of BC diagnosis (SHR: 0.44; 95%CI: 0.26–0.73 with I 2 = 78%). We also observed a borderline significant improvement in disease free survival for subjects treated with BB (SHR: 0.71, 95%CI: 0.19–1.03). No association of ACEi/ARB use with disease free and overall survival was found. In conclusion, we report epidemiological evidence that BB improve BC‐specific survival. Clinical trials addressing this hypothesis are warranted. What's new? Antihypertensive drugs are linked to reductions in tumor metastasis, tumor recurrence and cancer‐specific mortality, benefits possibly related to the drugs’ ability to blunt the effects of stress hormones and inflammation. Results from previous observational studies are controversial, however, particularly concerning breast cancer and whether taking antihypertensive drugs can actually improve survival. In the present meta‐analysis, which included some 46,265 patients from 11 articles, breast cancer‐specific survival was found to be significantly improved among patients who were undergoing treatment with beta‐blockers at the time of cancer diagnosis. The authors declare a need for further exploration in clinical trials. Breast cancer (BC) is the second leading cause of cancer death among women in Western Countries. Beta‐blocker (BB) drugs, angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) were suggested to have a favorable role in the development and progression of BC. We have performed a meta‐analysis to clarify the potential benefits of these drugs on BC survival. A total number of 46 265 BC patients from eleven papers were included, ten independent studies on BB use and seven on ACEi/ARB use. The summary hazard ratio (SHR) was estimated by pooling the study‐specific estimates with random effects models and maximum likelihood estimation. We assessed the homogeneity of the effects across studies and evaluated between‐study heterogeneity by meta‐regression and sensitivity analyses. We found a significant improvement in BC specific survival for patients treated with BB drugs at the time of BC diagnosis (SHR: 0.44; 95%CI: 0.26–0.73 with I2 = 78%). We also observed a borderline significant improvement in disease free survival for subjects treated with BB (SHR: 0.71, 95%CI: 0.19–1.03). No association of ACEi/ARB use with disease free and overall survival was found. In conclusion, we report epidemiological evidence that BB improve BC‐specific survival. Clinical trials addressing this hypothesis are warranted. What's new? Antihypertensive drugs are linked to reductions in tumor metastasis, tumor recurrence and cancer‐specific mortality, benefits possibly related to the drugs’ ability to blunt the effects of stress hormones and inflammation. Results from previous observational studies are controversial, however, particularly concerning breast cancer and whether taking antihypertensive drugs can actually improve survival. In the present meta‐analysis, which included some 46,265 patients from 11 articles, breast cancer‐specific survival was found to be significantly improved among patients who were undergoing treatment with beta‐blockers at the time of cancer diagnosis. The authors declare a need for further exploration in clinical trials. |
| Author | Cipolla, Carlo Botteri, Edoardo Raimondi, Sara Rotmensz, Nicole DeCensi, Andrea Munzone, Elisabetta Gandini, Sara |
| Author_xml | – sequence: 1 givenname: Sara surname: Raimondi fullname: Raimondi, Sara organization: European Institute of Oncology – sequence: 2 givenname: Edoardo surname: Botteri fullname: Botteri, Edoardo organization: European Institute of Oncology – sequence: 3 givenname: Elisabetta surname: Munzone fullname: Munzone, Elisabetta organization: European Institute of Oncology – sequence: 4 givenname: Carlo surname: Cipolla fullname: Cipolla, Carlo organization: European Institute of Oncology – sequence: 5 givenname: Nicole surname: Rotmensz fullname: Rotmensz, Nicole organization: European Institute of Oncology – sequence: 6 givenname: Andrea surname: DeCensi fullname: DeCensi, Andrea organization: Wolfson Institute of Preventive Medicine, Queen Mary University of London – sequence: 7 givenname: Sara surname: Gandini fullname: Gandini, Sara organization: European Institute of Oncology |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26916107$$D View this record in MEDLINE/PubMed |
| BookMark | eNp90c1u1DAQB3ALFdFt4cALIEtcQCKtx_lw3Bta8VFUiQP0HDnOpHhJ7MV2tgonHoGn4MF4EsymRagSnCx5fjMazf-IHFhnkZDHwE6AMX5qNvokZ6zi98gKmBQZ41AekFWqsUxAXh2SoxA2jAGUrHhADnkloQImVuTHZUDqetpiVD-_fW8Hpz-jDy-oslfGRbTB2PSvnd2hj8ZeUbRf5xGpsZ9Ma6LzIdHub049atymCr2dthetRxUi1cpq9DRMfmd2ajijH-YQcVTR6NS4M3i91-Oyj7JqmIMJD8n9Xg0BH928x-Ty9auP67fZxfs35-uXF5kuyoJnRQW8ACU4r2Vb90xXUvdS9hK1rFRZl0J1UIiqEEJ2Hc8Zz3MBEkXauGuhzY_Js2Xu1rsvE4bYjCZoHAZl0U2hAVFDWYBgkOjTO3TjJp_2XRQTuRR1Uk9u1NSO2DVbb0bl5-Y2gQSeL0B7F4LH_g8B1vxOt0npNvt0kz29Y7WJ6XLORq_M8L-OazPg_O_Rzfm79dLxC2uAuwQ |
| CitedBy_id | crossref_primary_10_1002_ajh_24582 crossref_primary_10_15829_1560_4071_2021_4703 crossref_primary_10_17816_clinpract629938 crossref_primary_10_1093_aje_kwz106 crossref_primary_10_1158_1541_7786_MCR_17_0132 crossref_primary_10_3390_cells9041036 crossref_primary_10_1080_0284186X_2017_1407040 crossref_primary_10_1016_j_bj_2019_02_003 crossref_primary_10_1111_apha_14164 crossref_primary_10_17816_clinpract567924 crossref_primary_10_1186_s12935_023_03080_9 crossref_primary_10_1126_scitranslmed_aan5616 crossref_primary_10_1097_FJC_0000000000001600 crossref_primary_10_1007_s10286_020_00724_y crossref_primary_10_3389_fphar_2022_1049640 crossref_primary_10_1016_j_phrs_2019_01_037 crossref_primary_10_1177_20420986231181338 crossref_primary_10_1007_s10552_021_01485_3 crossref_primary_10_1016_j_phrs_2019_104587 crossref_primary_10_3389_fphar_2023_1325050 crossref_primary_10_1093_ajh_hpac066 crossref_primary_10_1007_s10555_023_10095_1 crossref_primary_10_1042_CS20200307 crossref_primary_10_1161_CIR_0000000000000556 crossref_primary_10_1007_s10549_024_07263_4 crossref_primary_10_3390_cancers12113252 crossref_primary_10_1097_CEJ_0000000000000544 crossref_primary_10_1016_j_ijcard_2017_03_132 crossref_primary_10_1126_sciadv_aay0044 crossref_primary_10_1158_1055_9965_EPI_20_0711 crossref_primary_10_1002_jcb_28955 crossref_primary_10_3389_fphar_2020_610157 crossref_primary_10_1007_s11897_018_0401_0 crossref_primary_10_1038_s41598_018_23630_w crossref_primary_10_1093_annonc_mdx264 crossref_primary_10_3892_mmr_2017_6898 crossref_primary_10_1016_j_esmoop_2021_100066 crossref_primary_10_1016_j_compbiomed_2016_07_010 crossref_primary_10_3892_ol_2024_14667 crossref_primary_10_1097_MD_0000000000019075 crossref_primary_10_1161_CIRCRESAHA_121_318223 crossref_primary_10_1007_s10549_017_4129_4 crossref_primary_10_1016_j_ccell_2017_02_005 crossref_primary_10_1080_2162402X_2023_2284486 crossref_primary_10_1042_BSR20200721 crossref_primary_10_1093_eurheartj_ehae105 crossref_primary_10_1080_10942912_2018_1460756 crossref_primary_10_1177_1933719119828066 crossref_primary_10_1016_j_jogn_2016_10_001 crossref_primary_10_1158_1055_9965_EPI_19_0147 crossref_primary_10_1007_s10911_017_9371_1 crossref_primary_10_3389_fphar_2024_1423502 crossref_primary_10_1002_ejhf_1811 crossref_primary_10_1038_s41440_024_02086_8 crossref_primary_10_3389_fphys_2017_00276 crossref_primary_10_2174_1871520621666211021143255 crossref_primary_10_3390_cancers14184372 crossref_primary_10_1158_1078_0432_CCR_16_0695 crossref_primary_10_1097_MD_0000000000006394 crossref_primary_10_1016_j_urolonc_2016_08_013 crossref_primary_10_1016_j_clbc_2020_01_007 crossref_primary_10_1097_PPO_0000000000000360 |
| Cites_doi | 10.1038/nrclinonc.2011.123 10.1158/1940-6207.CAPR-08-0238 10.1016/S1470-2045(10)70260-6 10.4065/84.8.718 10.1200/JCO.2010.27.9752 10.1200/JCO.2002.20.1.42 10.1038/nrc2945 10.3109/07357907.2011.616252 10.1200/JCO.2010.31.5143 10.1007/s10549-009-0591-y 10.1200/JCO.2009.26.9357 10.1007/s10552-008-9203-0 10.1007/s10549-014-2870-5 10.1200/JCO.2010.33.4441 10.1158/0008-5472.CAN-10-0522 10.1002/sim.1040 10.1016/j.vph.2010.08.002 10.1186/1741-7015-12-28 10.18632/oncotarget.197 10.1200/JCO.2010.29.2730 10.2337/dc12-0788 10.1158/1055-9965.EPI-08-0871 10.1016/j.pharmthera.2010.02.002 10.1158/1940-6207.CAPR-13-0424 10.7150/jca.6888 10.1038/nrc2870 10.1093/carcin/bgn171 10.1001/jama.1992.03480090092034 10.1007/s10549-013-2553-7 10.1158/1055-9965.EPI-08-0544 10.1016/j.phrs.2009.05.005 10.1007/s10549-011-1505-3 10.1200/JCO.2012.43.9190 10.1093/ije/dyt196 10.1111/j.1365-2125.2011.03980.x 10.1200/JCO.2009.27.3011 10.2174/092986709788186048 10.1200/JCO.2010.33.5422 10.1007/s10549-013-2654-3 10.18632/oncotarget.343 10.1002/sim.698 10.1038/nm1447 10.1007/s10552-010-9590-x 10.1007/s10549-015-3311-9 10.1016/S0006-291X(02)00496-5 10.1159/000371871 10.1016/j.tem.2005.07.009 |
| ContentType | Journal Article |
| Copyright | 2016 UICC 2016 UICC. |
| Copyright_xml | – notice: 2016 UICC – notice: 2016 UICC. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TO 7U9 H94 K9. 7X8 |
| DOI | 10.1002/ijc.30062 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0215 |
| EndPage | 219 |
| ExternalDocumentID | 4022778851 26916107 10_1002_ijc_30062 IJC30062 |
| Genre | article Meta-Analysis Journal Article |
| GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RX1 RYL SUPJJ TEORI UB1 UDS V2E V8K V9Y W2D W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XPP XV2 ZZTAW ~IA ~WT .55 .GJ .Y3 31~ 3O- 53G 8WZ A6W AAMMB AANHP AAYXX ABEFU ABEML ACBWZ ACRPL ACSCC ACYXJ ADNMO AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AHEFC AI. AIDQK AIDYY AIQQE ASPBG AVWKF AZFZN BDRZF CITATION EX3 FEDTE GLUZI HF~ HVGLF M6P PALCI RJQFR SAMSI VH1 WOW X7M Y6R ZGI ZXP CGR CUY CVF ECM EIF NPM 7T5 7TO 7U9 H94 K9. 7X8 |
| ID | FETCH-LOGICAL-c4542-461241a72289b8f0c69cf99f9ec96a5857ad14764779dd230233719e7ecedb1b3 |
| IEDL.DBID | DR2 |
| ISSN | 0020-7136 |
| IngestDate | Fri Jul 11 11:54:52 EDT 2025 Sun Jul 13 03:23:26 EDT 2025 Mon Jul 21 06:02:23 EDT 2025 Thu Apr 24 23:09:59 EDT 2025 Mon Sep 15 11:46:48 EDT 2025 Wed Jan 22 16:46:13 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | antihypertensive drugs beta-blockers breast cancer angiotensin-converting enzyme inhibitors angiotensin receptor blockers prognosis |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2016 UICC. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4542-461241a72289b8f0c69cf99f9ec96a5857ad14764779dd230233719e7ecedb1b3 |
| Notes | Conflicts of interest No conflict to disclose ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.30062 |
| PMID | 26916107 |
| PQID | 1781073978 |
| PQPubID | 105430 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1781541701 proquest_journals_1781073978 pubmed_primary_26916107 crossref_primary_10_1002_ijc_30062 crossref_citationtrail_10_1002_ijc_30062 wiley_primary_10_1002_ijc_30062_IJC30062 |
| PublicationCentury | 2000 |
| PublicationDate | 1 July 2016 |
| PublicationDateYYYYMMDD | 2016-07-01 |
| PublicationDate_xml | – month: 07 year: 2016 text: 1 July 2016 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | International journal of cancer |
| PublicationTitleAlternate | Int J Cancer |
| PublicationYear | 2016 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2010; 10 2010; 53 2009; 84 2013; 4 2011; 2 2006; 12 2002; 294 2009; 60 1991; 11 2008; 19 1992; 267 2010; 126 2013; 42 2008; 17 2010; 121 2013; 140 2011; 12 2012; 35 2014; 60 2011; 8 2001; 20 2010; 21 2009; 13 2015; 150 2010; 1 2011; 129 2002; 20 2010; 28 2008; 29 2013; 31 2002; 21 2013; 139 2003; 9 2011; 72 2015 2010; 70 2005; 16 2014; 144 2009; 2 2014; 7 2011; 29 2009; 16 2014; 12 2009; 18 e_1_2_6_51_1 Draoui A (e_1_2_6_47_1) 1991; 11 e_1_2_6_32_1 e_1_2_6_30_1 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_17_1 Lutgendorf SK (e_1_2_6_38_1) 2003; 9 e_1_2_6_15_1 e_1_2_6_43_1 e_1_2_6_20_1 e_1_2_6_41_1 e_1_2_6_9_1 e_1_2_6_5_1 e_1_2_6_7_1 e_1_2_6_24_1 e_1_2_6_49_1 e_1_2_6_3_1 e_1_2_6_28_1 e_1_2_6_45_1 e_1_2_6_26_1 e_1_2_6_52_1 e_1_2_6_10_1 Hajighasemi F (e_1_2_6_22_1) 2009; 13 e_1_2_6_31_1 e_1_2_6_50_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_16_1 e_1_2_6_37_1 e_1_2_6_42_1 e_1_2_6_21_1 e_1_2_6_40_1 e_1_2_6_8_1 e_1_2_6_4_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_48_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_29_1 e_1_2_6_44_1 e_1_2_6_27_1 e_1_2_6_46_1 |
| References_xml | – volume: 18 start-page: 701 year: 2009 end-page: 5 article-title: Is it time to test metformin in breast cancer clinical trials? publication-title: Cancer Epidemiol Biomarkers Prev – volume: 31 start-page: 2265 year: 2013 end-page: 72 article-title: Use of beta‐blockers, angiotensin‐converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study publication-title: J Clin Oncol – volume: 21 start-page: 1615 year: 2010 end-page: 24 article-title: Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort publication-title: Cancer Causes Control – volume: 294 start-page: 441 year: 2002 end-page: 7 article-title: Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis publication-title: Biochem Biophys Res Commun – volume: 12 start-page: 939 year: 2006 end-page: 44 article-title: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma publication-title: Nat Med – volume: 53 start-page: 200 year: 2010 end-page: 8 article-title: Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells publication-title: Vascul Pharmacol – volume: 139 start-page: 507 year: 2013 end-page: 13 article-title: Beta blockers and angiotensin‐converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use publication-title: Breast Cancer Res Treat – volume: 267 start-page: 1244 year: 1992 end-page: 52 article-title: The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis publication-title: JAMA – volume: 84 start-page: 718 year: 2009 end-page: 29 article-title: Beta‐blocker use for the stages of heart failure publication-title: Mayo Clin Proc – volume: 20 start-page: 42 year: 2002 end-page: 51 article-title: Fasting insulin and outcome in early‐stage breast cancer: results of a prospective cohort study publication-title: J Clin Oncol – volume: 16 start-page: 1850 year: 2009 end-page: 62 article-title: Adrenoceptors: non conventional target for breast cancer? publication-title: Curr Med Chem – volume: 12 year: 2014 article-title: Drugs affecting the renin‐angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts publication-title: BMC Med – volume: 60 start-page: 438 year: 2009 end-page: 45 article-title: Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase‐9 secretion publication-title: Pharmacol Res – volume: 2 start-page: 797 year: 2011 end-page: 809 article-title: Propranolol potentiates the anti‐angiogenic effects and anti‐tumor efficacy of chemotherapy agents: implication in breast cancer treatment publication-title: Oncotarget – volume: 9 start-page: 4514 year: 2003 end-page: 21 article-title: Stress‐related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines publication-title: Clin Cancer Res – volume: 28 start-page: 4019 year: 2010 end-page: 21 article-title: Host factors and cancer outcome publication-title: J Clin Oncol – volume: 150 start-page: 219 year: 2015 end-page: 29 article-title: Antihypertensive medication use and incident breast cancer in women publication-title: Breast Cancer Res Treat – volume: 7 start-page: 867 year: 2014 end-page: 85 article-title: Metformin and cancer risk and mortality: a systematic review and meta‐analysis taking into account biases and confounders publication-title: Cancer Prev Res (Phila) – volume: 29 start-page: 2645 year: 2011 end-page: 52 article-title: Beta‐blocker use is associated with improved relapse‐free survival in patients with triple‐negative breast cancer publication-title: J Clin Oncol – volume: 28 start-page: 4074 year: 2010 end-page: 80 article-title: Weight, physical activity, diet, and prognosis in breast and gynecologic cancers publication-title: J Clin Oncol – volume: 10 start-page: 514 year: 2010 end-page: 23 article-title: Envisioning the future of early anticancer drug development publication-title: Nat Rev Cancer – volume: 12 start-page: 65 year: 2011 end-page: 82 article-title: Antihypertensive drugs and risk of cancer: network meta‐analyses and trial sequential analyses of 324,168 participants from randomised trials publication-title: Lancet Oncol – volume: 2 start-page: 850 year: 2009 end-page: 61 article-title: A model of gene‐environment interaction reveals altered mammary gland gene expression and increased tumor growth following social isolation publication-title: Cancer Prev Res (Phila) – volume: 29 start-page: 40 year: 2011 end-page: 6 article-title: Diabetes mellitus and breast cancer outcomes: a systematic review and meta‐analysis publication-title: J Clin Oncol – volume: 21 start-page: 589 year: 2002 end-page: 624 article-title: Advanced methods in meta‐analysis: multivariate approach and meta‐regression publication-title: Stat Med – volume: 28 start-page: 4410 year: 2010 end-page: 6 article-title: Alcohol consumption and breast cancer recurrence and survival among women with early‐stage breast cancer: the life after cancer epidemiology study publication-title: J Clin Oncol – volume: 29 start-page: 2635 year: 2011 end-page: 44 article-title: Beta blockers and breast cancer mortality: a population‐ based study publication-title: J Clin Oncol – volume: 126 start-page: 159 year: 2010 end-page: 72 article-title: Sympathetic nervous activation in obesity and the metabolic syndrome–causes, consequences and therapeutic implications publication-title: Pharmacol Ther – volume: 11 start-page: 677 year: 1991 end-page: 80 article-title: Beta‐adrenergic receptors in human breast cancer: identification, characterization and correlation with progesterone and estradiol receptors publication-title: Anticancer Res – year: 2015 – volume: 17 start-page: 3319 year: 2008 end-page: 24 article-title: Triple‐negative breast cancer and obesity in a rural Appalachian population. publication-title: Epidemiol Biomarkers Prev – volume: 13 start-page: 223 year: 2009 end-page: 8 article-title: Effect of propranolol on angiogenic factors in human hematopoietic cell lines in vitro publication-title: Iran Biomed J – volume: 29 start-page: 585 year: 2011 end-page: 93 article-title: Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins publication-title: Cancer Invest – volume: 144 start-page: 405 year: 2014 end-page: 16 article-title: Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer publication-title: Breast Cancer Res Treat – volume: 29 start-page: 1675 year: 2008 end-page: 84 article-title: The renin‐angiotensin system and malignancy publication-title: Carcinogenesis – volume: 70 start-page: 7042 year: 2010 end-page: 52 article-title: The sympathetic nervous system induces a metastatic switch in primary breast cancer publication-title: Cancer Res – volume: 16 start-page: 293 year: 2005 end-page: 9 article-title: Angiotensin receptors: a new role in cancer? publication-title: Trends Endocrinol Metab – volume: 35 start-page: 2665 year: 2012 end-page: 73 article-title: Metformin and the risk of cancer: time‐related biases in observational studies publication-title: Diabetes Care – volume: 72 start-page: 157 year: 2011 end-page: 61 article-title: Does beta‐adrenoceptor blocker therapy improve cancer survival? Findings from a population‐based retrospective cohort study publication-title: Br J Clin Pharmacol – volume: 121 start-page: 479 year: 2010 end-page: 83 article-title: The association of metabolic syndrome with triple‐negative breast cancer publication-title: Breast Cancer Res Treat – volume: 10 start-page: 745 year: 2010 end-page: 59 article-title: The renin‐angiotensin system and cancer: old dog, new tricks publication-title: Nat Rev Cancer – volume: 28 start-page: 4094 year: 2010 end-page: 9 article-title: Host factors and cancer progression: biobehavioral signaling pathways and interventions publication-title: J Clin Oncol – volume: 4 start-page: 549 year: 2013 end-page: 56 article-title: Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes publication-title: J Cancer – volume: 140 start-page: 567 year: 2013 end-page: 75 article-title: Therapeutic effect of beta‐blockers in triple‐negative breast cancer postmenopausal women publication-title: Breast Cancer Res Treat – volume: 8 start-page: 511 year: 2011 end-page: 2 article-title: Targeted therapies: Using beta‐blockers to inhibit breast cancer progression publication-title: Nat Rev Clin Oncol – volume: 42 start-page: 1852 year: 2013 end-page: 61 article-title: Beta‐blocker usage and breast cancer survival: a nested case‐control study within a UK clinical practice research datalink cohort publication-title: Int J Epidemiol – volume: 129 start-page: 549 year: 2011 end-page: 56 article-title: Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort publication-title: Breast Cancer Res Treat – volume: 60 start-page: 288 year: 2014 end-page: 9 article-title: beta‐Blocker Use and Risk of Recurrence in Patients with Early Breast Cancer publication-title: Chemotherapy – volume: 20 start-page: 641 year: 2001 end-page: 54 article-title: A comparison of methods to detect publication bias in meta‐analysis publication-title: Stat Med – volume: 1 start-page: 628 year: 2010 end-page: 38 article-title: Beta‐blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival publication-title: Oncotarget – volume: 19 start-page: 1319 year: 2008 end-page: 28 article-title: Pre‐diagnosis body mass index, post‐diagnosis weight change, and prognosis among women with early stage breast cancer publication-title: Cancer Causes Control – ident: e_1_2_6_20_1 doi: 10.1038/nrclinonc.2011.123 – ident: e_1_2_6_48_1 doi: 10.1158/1940-6207.CAPR-08-0238 – ident: e_1_2_6_28_1 doi: 10.1016/S1470-2045(10)70260-6 – ident: e_1_2_6_13_1 doi: 10.4065/84.8.718 – volume: 11 start-page: 677 year: 1991 ident: e_1_2_6_47_1 article-title: Beta‐adrenergic receptors in human breast cancer: identification, characterization and correlation with progesterone and estradiol receptors publication-title: Anticancer Res – ident: e_1_2_6_10_1 doi: 10.1200/JCO.2010.27.9752 – ident: e_1_2_6_5_1 doi: 10.1200/JCO.2002.20.1.42 – ident: e_1_2_6_27_1 doi: 10.1038/nrc2945 – ident: e_1_2_6_29_1 doi: 10.3109/07357907.2011.616252 – ident: e_1_2_6_3_1 doi: 10.1200/JCO.2010.31.5143 – ident: e_1_2_6_44_1 doi: 10.1007/s10549-009-0591-y – ident: e_1_2_6_4_1 doi: 10.1200/JCO.2009.26.9357 – ident: e_1_2_6_6_1 doi: 10.1007/s10552-008-9203-0 – ident: e_1_2_6_42_1 doi: 10.1007/s10549-014-2870-5 – ident: e_1_2_6_16_1 doi: 10.1200/JCO.2010.33.4441 – ident: e_1_2_6_18_1 doi: 10.1158/0008-5472.CAN-10-0522 – ident: e_1_2_6_35_1 doi: 10.1002/sim.1040 – ident: e_1_2_6_23_1 doi: 10.1016/j.vph.2010.08.002 – ident: e_1_2_6_37_1 doi: 10.1186/1741-7015-12-28 – ident: e_1_2_6_14_1 doi: 10.18632/oncotarget.197 – volume: 9 start-page: 4514 year: 2003 ident: e_1_2_6_38_1 article-title: Stress‐related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines publication-title: Clin Cancer Res – ident: e_1_2_6_9_1 doi: 10.1200/JCO.2010.29.2730 – ident: e_1_2_6_52_1 doi: 10.2337/dc12-0788 – ident: e_1_2_6_11_1 doi: 10.1158/1055-9965.EPI-08-0871 – ident: e_1_2_6_46_1 doi: 10.1016/j.pharmthera.2010.02.002 – ident: e_1_2_6_12_1 doi: 10.1158/1940-6207.CAPR-13-0424 – ident: e_1_2_6_31_1 doi: 10.7150/jca.6888 – ident: e_1_2_6_24_1 doi: 10.1038/nrc2870 – ident: e_1_2_6_51_1 doi: 10.1093/carcin/bgn171 – ident: e_1_2_6_45_1 doi: 10.1001/jama.1992.03480090092034 – ident: e_1_2_6_32_1 doi: 10.1007/s10549-013-2553-7 – ident: e_1_2_6_43_1 doi: 10.1158/1055-9965.EPI-08-0544 – ident: e_1_2_6_21_1 doi: 10.1016/j.phrs.2009.05.005 – ident: e_1_2_6_30_1 doi: 10.1007/s10549-011-1505-3 – ident: e_1_2_6_33_1 doi: 10.1200/JCO.2012.43.9190 – ident: e_1_2_6_41_1 doi: 10.1093/ije/dyt196 – ident: e_1_2_6_40_1 doi: 10.1111/j.1365-2125.2011.03980.x – ident: e_1_2_6_8_1 doi: 10.1200/JCO.2009.27.3011 – ident: e_1_2_6_19_1 doi: 10.2174/092986709788186048 – volume: 13 start-page: 223 year: 2009 ident: e_1_2_6_22_1 article-title: Effect of propranolol on angiogenic factors in human hematopoietic cell lines in vitro publication-title: Iran Biomed J – ident: e_1_2_6_2_1 – ident: e_1_2_6_15_1 doi: 10.1200/JCO.2010.33.5422 – ident: e_1_2_6_17_1 doi: 10.1007/s10549-013-2654-3 – ident: e_1_2_6_25_1 doi: 10.18632/oncotarget.343 – ident: e_1_2_6_36_1 doi: 10.1002/sim.698 – ident: e_1_2_6_39_1 doi: 10.1038/nm1447 – ident: e_1_2_6_7_1 doi: 10.1007/s10552-010-9590-x – ident: e_1_2_6_49_1 doi: 10.1007/s10549-015-3311-9 – ident: e_1_2_6_50_1 doi: 10.1016/S0006-291X(02)00496-5 – ident: e_1_2_6_34_1 doi: 10.1159/000371871 – ident: e_1_2_6_26_1 doi: 10.1016/j.tem.2005.07.009 |
| SSID | ssj0011504 |
| Score | 2.4618526 |
| SecondaryResourceType | review_article |
| Snippet | Breast cancer (BC) is the second leading cause of cancer death among women in Western Countries. Beta‐blocker (BB) drugs, angiotensin‐converting enzyme... Breast cancer (BC) is the second leading cause of cancer death among women in Western Countries. Beta-blocker (BB) drugs, angiotensin-converting enzyme... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 212 |
| SubjectTerms | Adrenergic beta-Antagonists - administration & dosage Angiotensin Receptor Antagonists - administration & dosage angiotensin receptor blockers Angiotensin-Converting Enzyme Inhibitors - administration & dosage angiotensin‐converting enzyme inhibitors Antihypertensive Agents - administration & dosage antihypertensive drugs beta‐blockers Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - epidemiology Breast Neoplasms - pathology Cancer Clinical trials Disease-Free Survival Drugs Enzymes Female Humans Hypertension - drug therapy Medical research Meta-analysis Mortality prognosis Proportional Hazards Models Systematic review |
| Title | Use of beta‐blockers, angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta‐analysis |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.30062 https://www.ncbi.nlm.nih.gov/pubmed/26916107 https://www.proquest.com/docview/1781073978 https://www.proquest.com/docview/1781541701 |
| Volume | 139 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0020-7136 databaseCode: DR2 dateStart: 19960101 customDbUrl: isFulltext: true eissn: 1097-0215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011504 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB5VPaBeoLT8LC2VizhwINvNnxPDCVVUbaVyAFbqASnybwml2aqbPdATj8BT8GA8CTN2ElqgEuIWJRPbcWbGn-3xNwBPTeFsqngaOeeSCPGtiXDabCLHjaUBWuR-TffoDd-fZofH-fESvOzPwgR-iGHBjSzD-2sycKnmO79IQ-tPepzSEUD0v3Ga-y3atwN1FAGdjoF5EuFEjPesQpNkZ3jz-lj0B8C8jlf9gLN3Bz70TQ1xJqfjRavG-vI3Fsf__JZVuN0BUfYqaM5dWLLNGtw66rba1-H7dG7ZzDFlW_nj6zeFg94pQsXnTDYn9czHvTd430etExPBCbPN5Zczy-rmY61qSuKDouaqOEPvas_xCetL8xKK4uJbpkn_Lth8gc4L1f8FezeQTLNwwMZLn4X2yI5M5R5M916_392PuqQOkc7yDNUBIVUWyyLBmZ4q3URzoZ0QTlgtuMTJSyFNnBV0PlYYk1BOo7SIhS2whUbFKr0Py82ssQ-BIZbUiutkUooys5JL5YQiSnllHeHgETzrf2-lO8ZzSrzxuQpczUmF_V75fh_Bk0H0PNB8_E1os9eRqrP0eRUXZUy7nUU5gu3hMdoobbzIxs4WQSbPiPl-BA-Cbg21JBwBOpaAjfUacnP11cHhrr949O-iG7CCCI-H-OJNWG4vFvYxoqhWbXlz-QmcMB1x |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgGX8qYLBQziwIFsN491YsQFFapt6fYAXamXKrIdu6SPbNXNHuipP6G_gh_GL2HGTgLlISFuUTKxHWfG_mzPfAPwokitiRWPA2ttFCC-LQJcNheB5YWhCVoM3Z7ueJuPJsnm7nB3Ad60sTCeH6LbcCPLcOM1GThtSK_-YA0tD3Q_phjAK3CVzufILN997MijCOo0HMyDAJdivOUVGkSr3auXZ6PfIOZlxOqmnPWbsNc21nuaHPbnterrs194HP_3a27BUoNF2VuvPLdhwVR34Nq4OW2_C18nM8OmlilTy2_nFwrnvUNEi6-YrPbLqXN9r_C-c1wnMoJ9ZqqzL8eGldXnUpWUxwdFi5_FGQ6w5gSfsLY0J6HINb5mmlTwlM3mOH6hBbxmnzqeaeZjbJz0sW-PbPhU7sFk_f3O2iho8joEOhkmqBGIqpJQphEu9lRmB5oLbYWwwmjBJa5fUlmESUohsqIoIkprFKehMCm2sFChiu_DYjWtzDIwhJNacR0NMpElRnKprFDEKq-MJSjcg5ft_811Q3pOuTeOck_XHOXY77nr9x4870RPPNPHn4RWWiXJG2Of5WGahXTgmWY9eNY9RjOlsxdZmencywwTIr_vwQOvXF0tEUeMjiVgY52K_L36fGNzzV08_HfRp3B9tDPeyrc2tj88ghsI-Lh3N16Bxfp0bh4jqKrVE2c73wFLxyGN |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVceD8WChjEgQPZbh7rxHBChVVbaIWAlXpAivwsoTS76mYP9MRP4Ffww_glzNhJoDwkxC1KJvbEmbG_scefAR6Y3NlU8TRyziUR4lsTYdhsIseNpQFajP2c7u4e35pmO_vj_RV40u2FCfwQ_YQbeYbvr8nB58Zt_CANrT7oYUpbAM_A2YxjdEWI6HXPHUVIp6VgHkUYifGOVmiUbPSvnh6MfkOYpwGrH3EmF-Bdp2tINDkcLhs11Ce_0Dj-58dchPMtEmVPg-lcghVbX4a13Xat_Qp8nS4smzmmbCO_ff6icNQ7RKz4iMn6oJr5xPca7_u0daIiOGC2Pvl0ZFlVv69URaf4oKj5WZxh92rn-IR1pXkJRYnxDdNkgMdsscTeC-3_MXvTs0yzsMPGSx8FfWTLpnIVppPnbze3ovZUh0hn4wztATFVFss8wVBPFW6kudBOCCesFlxi9JJLE2c5bZAVxiR0qFGax8LmqKFRsUqvwWo9q-0NYAgmteI6GRWiyKzkUjmhiFNeWUdAeAAPu99b6pbynE7e-FgGsuakxHYvfbsP4H4vOg88H38SWu9spGxdfVHGeRHTcmdeDOBe_xidlFZeZG1nyyAzzoj6fgDXg231tSQcETqWgMp6C_l79eX2zqa_uPnvondh7dWzSflye-_FLTiHaI-HXON1WG2Ol_Y2IqpG3fGe8x3e0yA8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+beta%E2%80%90blockers%2C+angiotensin%E2%80%90converting+enzyme+inhibitors+and+angiotensin+receptor+blockers+and+breast+cancer+survival%3A+Systematic+review+and+meta%E2%80%90analysis&rft.jtitle=International+journal+of+cancer&rft.au=Raimondi%2C+Sara&rft.au=Botteri%2C+Edoardo&rft.au=Munzone%2C+Elisabetta&rft.au=Cipolla%2C+Carlo&rft.date=2016-07-01&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=139&rft.issue=1&rft.spage=212&rft.epage=219&rft_id=info:doi/10.1002%2Fijc.30062&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_ijc_30062 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon |